Data from Phase III SCULPTURE trial shows efficacy of Cosentyx (secukinumab) to four years in plaque psoriasis- Novartis

Novartis announced new data from the extension study of the Phase III SCULPTURE trial showing Cosentyx (secukinumab) delivers efficacy in patients with moderate to severe plaque psoriasis out to four years of treatment. Almost clear skin (PASI 90) was achieved by 68.5% of patients at Year 1 (Week 52) and 61.9% of patients at Year 3 (Week 156), and was maintained at Year 4 (Week 208) in 66.4% of patients. In addition, completely clear skin (PASI 100) was achieved by 43.8% of patients at Year 1 and 41.7% of patients at Year 3, and was maintained at Year 4 in 43.5% of patients.

The historic standard goal of treatment, PASI 75 skin clearance, was achieved by 88.9% of patients at Year 1 and 78.4% of patients at Year 3, and was maintained by 88.5% of patients at Year 4. The most common adverse events (AEs) at Year 4 were nasopharyngitis (12.1%) and upper respiratory tract infection (3.5%) and were similar to those observed at Year 1. Results were presented at the 25th European Academy of Dermatology and Venereology Congress.